Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization

Gemtuzumab ozogamicin (GO) is a chemotherapy-conjugated anti-CD33 monoclonal antibody effective in some patients with acute myeloid leukemia (AML). The optimal treatment schedule and optimal timing of GO administration relative to other agents remains unknown. Conventional pharmacokinetic analysis h...

Descripción completa

Detalles Bibliográficos
Autores principales: Jager, Eva, van der Velden, Vincent H. J., te Marvelde, Jeroen G., Walter, Roland B., Agur, Zvia, Vainstein, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168467/
https://www.ncbi.nlm.nih.gov/pubmed/21915304
http://dx.doi.org/10.1371/journal.pone.0024265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168467/
https://www.ncbi.nlm.nih.gov/pubmed/21915304
http://dx.doi.org/10.1371/journal.pone.0024265

Ejemplares similares